AEONHealthcare · BiotechnologyThe 4 Wall Street analysts covering AEON Biopharma, Inc. hold a median 12-month price target of $2 — +1207.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 13 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores AEON Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AEON, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +1207.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Lake Street | Maintains | Buy | — |
| 14 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 July 2026 | Lake Street | Initiates | Buy | — |
| 8 Oct 2025 | Aegis Capital | Reiterates | Buy | — |
| 1 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Aug 2023 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AEON appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 94% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 95% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AEON Biopharma, Inc. has a market value of $12.3M and an enterprise value of $7.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$54.6M.
Free cash flow in the twelve months to 30 June 2026: −$13.6M.
Trailing P/E: 0.3×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AEON Biopharma, Inc. employs 8 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AEON Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AEON Biopharma submitted an investigational new drug application for a comparative pharmacodynamic study of ABP-450. The submission follows a recent FDA Type 2b meeting.
Why it matters — The filing marks a step in the development program for ABP-450 as a biosimilar.
AEON Biopharma received official minutes from its FDA Biosimilar Product Development Type 2b meeting for ABP-450, a proposed biosimilar to BOTOX. The FDA indicated that previously completed head-to-head studies versus BOTOX may be submitted as supportive evidence, with AEON expecting to advance the required bridging work and to submit an IND for a CMAP pharmacodynamic study in the fourth quarter of 2026.
Why it matters — The FDA feedback clarifies and potentially streamlines ABP-450's development path, giving AEON watchers greater visibility into the regulatory roadmap toward full-label U.S. market entry.
AEON Biopharma announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX under thermal and oxidative stress conditions. The results showed comparable rates of potency loss and similar site-specific oxidation patterns, providing additional analytical evidence supporting comparability and establishing the basis for AEON's planned multi-lot comparability study.
Why it matters — The results provide additional analytical evidence supporting ABP-450's comparability to BOTOX and lay the groundwork for AEON's planned multi-lot comparability study, marking progress in its biosimilar development program.
AEON Biopharma announced that its management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. The announcement was made on August 31, 2026.
Why it matters — AEON watchers would care because the investor meetings provide an opportunity for the company to engage directly with investors at a prominent industry conference.
AEON Biopharma has designated Paul Lee, M.D., Ph.D., a former Deputy Director of the FDA's Office of Neuroscience, as its Acting Chief Regulatory Officer. Dr. Lee previously advised the company on regulatory strategy for its biosimilar candidate ABP-450 through Clintrex Research LLC.
Why it matters — Adding a former FDA neuroscience leader as Acting Chief Regulatory Officer could strengthen AEON's regulatory approach as it seeks full-label U.S. market entry for ABP-450.
The 4 Wall Street analysts covering AEON Biopharma, Inc. have a median 12-month price target of $2, with estimates ranging from $1.2 to $2.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering AEON Biopharma, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AEON Biopharma, Inc. 45 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, AEON Biopharma, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +1207.2% from the last close, and Ticker Nerd's factor model ranks AEON Biopharma, Inc. 45 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AEON Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $2.1 over the next 12 months.
Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use.
The most recent item we track (GlobeNewsWire, 9 Nov 2026): "AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450". AEON Biopharma submitted an investigational new drug application for a comparative pharmacodynamic study of ABP-450. The submission follows a recent FDA Type 2b meeting.
Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use. The company’s current work centers on ABP-450 (prabotulinumtoxinA), a botulinum toxin product candidate being studied for medical conditions such as cervical dystonia and migraine. Its business is concentrated on advancing injectable treatments for debilitating disorders and building a portfolio around toxin-based therapeutics. Aeon Biopharma operates in the healthcare and biotechnology sectors, where it plays the role of a specialized clinical-stage developer working to expand treatment options in neurology and related therapeutic areas. Based in Irvine, California, the company’s Class A common stock provides public market exposure to its ongoing research, development, and commercialization efforts in the biopharmaceutical market.
CEO Mr. Robert Bancroft · 8 employees · United States · https://www.aeonbiopharma.com